Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Semin Hematol. 2021 Mar 3;58(2):78–84. doi: 10.1053/j.seminhematol.2021.02.004

Table 2:

Ongoing studies of targeted therapies for R/R PTCL

Drug category Agent(s) NCT Recruitment Status Eligible Diagnoses
Kinase Duvelisib NCT03372057 Recruiting PTCL-NOS, AITL, ALCL, NKTL
Duvelisib + romidepsin NCT02783625 Recruiting PTCL, CTCL
Tenalisib NCT03770000 Active, not recruiting TCL
Copanlisib + pembrolizumab NCT02535247 Active, not recruiting PTCL, transformed CTCL
Copanlisib + gemcitabine NCT03052933 Active, not recruiting PTCL, NKTL
Ruxolitinib NCT01712659 Recruiting ATL
TAK-659 + venetoclax NCT03357627 Active, not recruiting NHL
TAK-659 NCT02000934 Active, not recruiting Lymphoma
CPI-818 NCT03952078 Recruiting TCL
Tenalisib + romidepsin NCT03770000 Active, not recruiting TCL
Epigenetic Romidepsin + ixazomib NCT03547700 Active, not recruiting PTCL
Romidepsin + azacitidine + lenalidomide NCT04447027 Recruiting TCL
Romidepsin +/− pralatrexate +/− durvalumab +/− azacitidine NCT03161223 Recruiting PTCL
Valemetostat NCT02732275 Recruiting NHL
Azacitidine NCT03593018 Recruiting AITL
Other PRT1419 NCT04543305 Recruiting NHL
AMG 397 NCT03465540 Recruiting NHL
AZD5991 NCT03218683 Recruiting NHL
Venetoclax NCT03534180 Recruiting PTCL, transformed MF
Lenalidomide + brentuximab NCT03302728 Recruiting CD30+ PTCL
Lenalidomide + durvalumab NCT03011814 Recruiting PTCL

NKTL, NK/T-cell lymphoma; CTCL, cutaneous T-cell lymphoma; FTCL, follicular T-cell lymphoma; ATL, adult T-cell leukemia/lymphoma